Truveta’s Post

🚨‼️ WOW. Today Truveta announced that its #comparativeeffectiveness #study exploring #weightloss among patients taking #semaglutide (#Ozempic) and tirzepatide (Mounjaro) has been published in JAMA Internal Medicine. #rwd #rwe #healthoutcomes #clinicalresearch #ehrdata #weightlossdrugs #healthdatatrends #healthcaredata 👇🔥🎉

🎉 Exciting News! 🎉 I am thrilled to share that Truveta Research has been published in the Journal of the American Medical Association (JAMA)! This prestigious recognition underscores the dedication and hard work of our team in advancing healthcare through real-world data. Our groundbreaking study on weight loss trends among patients with overweight or obesity taking tirzepatide (Mounjaro) versus semaglutide (Ozempic) revealed that those taking tirzepatide were 3.2 times more likely than their counterparts taking semaglutide to achieve a 15% weight loss. This significant finding highlights the potential of data-driven insights to transform patient care and improve health outcomes. Congratulations to the entire Truveta Research team on this incredible accomplishment! 🚀👏 This is the largest comparative effectiveness study of its kind, and it's now peer reviewed. Learn more: https://tr.vet/3XVCPeS #Truveta #HealthcareInnovation #RealWorldData #JAMAPublished #WeightLoss #Tirzepatide #Semaglutide #ProudMoment

Nice to see this in depth review into Primary Aldosteronism Treatments finally published in Endocrine Reviews https://lnkd.in/egVSRynm

Another valuable finding provided by Arash Nayeri MD regarding #weightloss #obesity #diabetes from the JAMA Internal Medicine In 2021, Surpass-2 showed that Tirzepatide (branded as Mounjaro and Zepbound) was superior to Semaglutide (branded as Ozempic and Wegovy) for #diabetes management. To date, no head to head studies have been conducted comparing these two drugs for weight loss. Recently a retrospective cohort study of more than 18,000 patients showed than even when controlling for possible confounders, Tirzepatide leads to more significant weight loss than Semaglutide. This finding adds to the perception of Tirzepatide as a potentially more potent treatment option for #obesity and #diabetes. https://lnkd.in/gfD8PWGb

🔬 Exciting News! Our latest publication, “Assessing glomerular filtration rate with Proenkephalin,” marks a significant stride in kidney function evaluation. 🌟 In the realm of clinical practice, monitoring kidney health through creatinine-based estimations has been the norm for years. However, unlike traditional markers, Proenkephalin A shows promise in providing a more accurate and sensitive assessment of glomerular filtration rate (GFR). 📈 International scientists embarked on a pioneering multicenter study involving 1354 patients, both stable and critically ill. By utilizing cutting-edge methods and a data-driven approach, they successfully developed and validated a PENK-based equation for estimating GFR. 🌐 The PENK-based equation, encompassing factors like PENK levels, creatinine, and age, demonstrated impressive accuracy with a bias of only 0.5±15 mL/min/1.73m2 compared to traditional methods like MDRD and CKD-EPI. With a 83% accuracy (P30) in predicting GFR within ±30% of the measured value, the equation outperforms other established methods, setting a new benchmark for kidney function assessment. 📊 Notably, what sets the equation apart is its ability to deliver superior results without relying on sex or race data. This breakthrough underscores the importance of embracing more inclusive and advanced approaches to medical diagnostics. 💪 As we journey forward, we are excited about the potential of the PENK-based equation to transform how we understand and monitor kidney health. Here’s to innovation, collaboration, and a healthier future for all! 🌍🌱 #KidneyHealth #MedicalAdvancements #InnovationInMedicine https://lnkd.in/efV7vsH4

A simple principle in medicine: when you treat a patient and therapeutic targets exist, it is mandatory to control and adapt/correct your therapy! This is valuable not only for thyroid hormone replacement, but for many other diseases ... but avoid falling into the trap of treating only the numbers, and not the patient! Medicine is an art, supported by science!

🌟 Exciting Growth Ahead in the Endocrine Testing Industry! 🌟 The endocrine testing market is set to soar with an impressive 8.4% CAGR from 2023 to 2032! 🚀 This surge is driven by the rising prevalence of endocrine disorders and strong government support initiatives. 🩺💡 Stay tuned for groundbreaking advancements and innovations in endocrine health! 🌐🔬 #EndocrineHealth #MedicalInnovation #HealthcareGrowth #EndocrineTesting #HealthTech #MedicalAdvancements #FutureOfMedicine

We are pleased to announce positive study results demonstrating cardioprotective effects of subcutaneously administered cannabidiol in a model of heart failure with preserved ejection fraction. The study was presented by researchers from Tecnológico de Monterrey, Mexico at the Heart Failure Society of America Annual Scientific Meeting 2023. TecSalud is one of the Company’s international collaborating research centers working towards the common goal of developing products to advance the treatment of heart diseases. Dr. Andrew Hamer, Cardiol Therapeutics’ Chief Medical Officer and Head of Research & Development commented, “The importance of this study lies in the clinical relevance of the pre-clinical model itself, which was developed to mirror the comorbidities of hypertension, obesity, and metabolic dysfunction common to patients with heart failure with preserved ejection fraction. The results presented at the HFSA over the weekend demonstrated multiple cardioprotective effects of SUBQ administered cannabidiol and provide additional evidence in support of the development of CRD-38, our novel SUBQ formulation of cannabidiol intended for the treatment of heart failure. Furthermore, we believe our SUBQ formulation offers the potential for sustained drug release over time, allowing for less frequent administration and improved patient compliance in a chronic disease setting.” Please read the full press release: https://lnkd.in/g24hSBvK #PressRelease #News #StudyResults

Our #ATTR-QOL tool was designed to align with recommendations & standards from key regulatory bodies like #USFDA and #EMA, and thought leaders like #ISOQOL and the #PROTEUS Consortium for #PRO measure development: https://lnkd.in/eaW5pzvE We gathered input & guidance from a multidisciplinary group of experts including patients, clinicians, and life science companies, representing all relevant clinical specialties so that the #PRO measure could be useful across #ATTR #amyloidosis types and primary symptomatology. The #ATTRQOL covers 12 groups of specific health experiences comprising 7 health concepts (cardiac, neuropathic - peripheral, neuropathic - autonomic, and other; physical, role, and mental/emotional) that define 2 concepts of interest: #symptoms and #impacts

🔬📚 Exciting News Alert! 📚🔬 🌟 We are thrilled to announce the publication of our latest scientific research investigating the impact of fixed-dose treatments versus free-dose equivalents in the adherence and persistence to pharmacological therapies in patients with hypertension and/or dyslipidaemia! 🌟 📖 Our publication, titled "Impact of single-pill combinations versus free-equivalent combinations on adherence and persistence in patients with hypertension and dyslipidemia: a systematic literature review and meta-analysis," features a comprehensive systematic literature review and a rigorous meta-analysis, providing invaluable insights into optimizing treatment strategies for hypertension management. 💡 👏 A huge thank you to our dedicated team, Petar A., Pauline Le Nouveau, Dr Omar Irfan, and Maryse Kochoedo for their hard work, expertise, and commitment to advancing medical knowledge. This accomplishment would not have been possible without each and every one of you! 🙌 🔍 Curious to learn more? Dive into the full publication here Full article: https://lnkd.in/e6DuQnAa #ScientificResearch #HypertensionManagement #Publication #TeamWork #MedicalAdvancement #HEMA #AmarisHEMA